High Red Cell Distribution Width Independently Predicts Adverse Survival in Patients with Newly Diagnosed Skull Base Chordoma

References

• Stacchiotti S, Sommer J. Building a global consensus approach to chordoma: a position paper from the medical and patient community. Lancet Oncol. 2015;16(2):e71–e83. doi:10.1016/S1470-2045(14)71190-8
   PubMed Web of Science ®Google Scholar
• Stiller CA, Trama A, Serraino D, et al. Descriptive epidemiology of sarcomas in Europe: report from the RARECARE project. Eur J Cancer. 2013;49(3):684–695. doi:10.1016/j.ejca.2012.09.011
   PubMed Web of Science ®Google Scholar
• Chugh R, Tawbi H, Lucas DR, Biermann JS, Schuetze SM, Baker LH. Chordoma: the nonsarcoma primary bone tumor. Oncologist. 2007;12(11):1344–1350. doi:10.1634/theoncologist.12-11-1344
   PubMed Web of Science ®Google Scholar
• Walcott BP, Nahed BV, Mohyeldin A, Coumans J-V, Kahle KT, Ferreira MJ. Chordoma: current concepts, management, and future directions. Lancet Oncol. 2012;13(2):e69–e76. doi:10.1016/S1470-2045(11)70337-0
   PubMed Web of Science ®Google Scholar
• Stacchiotti S, Longhi A, Ferraresi V, et al. Phase II study of imatinib in advanced chordoma. J Clin Oncol. 2012;30(9):914–920. doi:10.1200/JCO.2011.35.3656
   PubMed Web of Science ®Google Scholar
• Stacchiotti S, Tamborini E, Lo Vullo S, et al. Phase II study on lapatinib in advanced EGFR-positive chordoma. Ann Oncol. 2013;24(7):1931–1936. doi:10.1093/annonc/mdt117
   PubMed Web of Science ®Google Scholar
• Sen C, Triana AI, Berglind N, Godbold J, Shrivastava RK. Clival chordomas: clinical management, results, and complications in 71 patients. J Neurosurg. 2010;113(5):1059–1071. doi:10.3171/2009.9.JNS08596
   PubMed Web of Science ®Google Scholar
• Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–867. doi:10.1038/nature01322
   PubMed Web of Science ®Google Scholar
• Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15(11):e493–503. doi:10.1016/S1470-2045(14)70263-3
   PubMed Web of Science ®Google Scholar
• Yodying H, Matsuda A, Miyashita M, et al. Prognostic significance of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in oncologic outcomes of esophageal cancer: a systematic review and meta-analysis. Ann Surg Oncol. 2016;23(2):646–654. doi:10.1245/s10434-015-4869-5
   PubMed Web of Science ®Google Scholar
• Koh CH, Bhoo-Pathy N, Ng KL, et al. Utility of pre-treatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as prognostic factors in breast cancer. Br J Cancer. 2015;113(1):150–158. doi:10.1038/bjc.2015.183
   PubMed Web of Science ®Google Scholar
• Allin KH, Bojesen SE, Nordestgaard BG. Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol. 2009;27(13):2217–2224. doi:10.1200/JCO.2008.19.8440
   PubMed Web of Science ®Google Scholar
• Salvagno GL, Sanchis-Gomar F, Picanza A, Lippi G. Red blood cell distribution width: a simple parameter with multiple clinical applications. Crit Rev Clin Lab Sci. 2015;52(2):86–105. doi:10.3109/10408363.2014.992064
   PubMed Web of Science ®Google Scholar
• Nagai H, Yuasa N, Takeuchi E, Miyake H, Yoshioka Y, Miyata K. The mean corpuscular volume as a prognostic factor for colorectal cancer. Surg Today. 2018;48(2):186–194. doi:10.1007/s00595-017-1575-x
   PubMed Web of Science ®Google Scholar
• Yoon HJ, Kim K, Nam YS, Yun JM, Park M. Mean corpuscular volume levels and all-cause and liver cancer mortality. Clin Chem Lab Med. 2016;54(7):1247–1257. doi:10.1515/cclm-2015-0786
   PubMed Web of Science ®Google Scholar
• Chen B, Ye B, Zhang J, Ying L, Chen Y. RDW to platelet ratio: a novel noninvasive index for predicting hepatic fibrosis and cirrhosis in chronic hepatitis B. PLoS One. 2013;8(7):e68780. doi:10.1371/journal.pone.0068780
   PubMed Web of Science ®Google Scholar
• Chen PC, Sung FC, Chien KL, Hsu HC, Su TC, Lee YT. Red blood cell distribution width and risk of cardiovascular events and mortality in a community cohort in Taiwan. Am J Epidemiol. 2010;171(2):214–220. doi:10.1093/aje/kwp360
   PubMed Web of Science ®Google Scholar
• Hu L, Li M, Ding Y, et al. Prognostic value of RDW in cancers: a systematic review and meta-analysis. Oncotarget. 2017;8(9):16027–16035. doi:10.18632/oncotarget.13784
   PubMedGoogle Scholar
• Smirne C, Grossi G, Pinato DJ, et al. Evaluation of the red cell distribution width as a biomarker of early mortality in hepatocellular carcinoma. Dig Liver Dis. 2015;47(6):488–494. doi:10.1016/j.dld.2015.03.011
   PubMedGoogle Scholar
• Jelkmann W. Proinflammatory cytokines lowering erythropoietin production. J Interferon Cytokine Res. 1998;18(8):555–559. doi:10.1089/jir.1998.18.555
   PubMed Web of Science ®Google Scholar
• Kiefer CR, Snyder LM. Oxidation and erythrocyte senescence. Curr Opin Hematol. 2000;7(2):113–116. doi:10.1097/00062752-200003000-00007
   PubMed Web of Science ®Google Scholar
• Li M, Bai J, Wang S, et al. Mean platelet volume and platelet distribution width serve as prognostic biomarkers in skull base chordoma: a retrospective study. BMC Cancer. 2020;20(1):988. doi:10.1186/s12885-020-07497-7
   PubMed Web of Science ®Google Scholar
• Al-Mefty O, Borba LA. Skull base chordomas: a management challenge. J Neurosurg. 1997;86(2):182–189. doi:10.3171/jns.1997.86.2.0182
   PubMed Web of Science ®Google Scholar
• Gui S, Zong X, Wang X, et al. Classification and surgical approaches for transnasal endoscopic skull base chordoma resection: a 6-year experience with 161 cases. Neurosurg Rev. 2016;39(2):321–332;discussion 332–323. doi:10.1007/s10143-015-0696-1
   PubMed Web of Science ®Google Scholar
• Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252–7259. doi:10.1158/1078-0432.CCR-04-0713
   PubMed Web of Science ®Google Scholar
• Yoshida N, Kosumi K, Tokunaga R, et al. Clinical importance of mean corpuscular volume as a prognostic marker after esophagectomy for esophageal cancer: a retrospective study. Ann Surg. 2020;271(3):494–501. doi:10.1097/SLA.0000000000002971
   PubMed Web of Science ®Google Scholar
• Pavanello S, Snenghi R, Nalesso A, Sartore D, Ferrara SD, Montisci M. Alcohol drinking, mean corpuscular volume of erythrocytes, and alcohol metabolic genotypes in drunk drivers. Alcohol (Fayetteville, NY). 2012;46(1):61–68. doi:10.1016/j.alcohol.2011.08.009
   PubMed Web of Science ®Google Scholar
• Qu X, Zhang T, Ma H, Sui P, Du J. Lower mean corpuscular hemoglobin concentration is associated with unfavorable prognosis of resected lung cancer. Fut Oncol. 2014;10(14):2149–2159. doi:10.2217/fon.14.121
   PubMed Web of Science ®Google Scholar
• Troppan KT, Melchardt T, Deutsch A, et al. The significance of pretreatment anemia in the era of R-IPI and NCCN-IPI prognostic risk assessment tools: a dual-center study in diffuse large B-cell lymphoma patients. Eur J Haematol. 2015;95(6):538–544. doi:10.1111/ejh.12529
   PubMed Web of Science ®Google Scholar
• von Meyenfeldt M. Cancer-associated malnutrition: an introduction. Eur J Oncol Nurs. 2005;9:S35–S38. doi:10.1016/j.ejon.2005.09.001
   PubMedGoogle Scholar
• Sun K, Chen S, Xu J, Li G, He Y. The prognostic significance of the prognostic nutritional index in cancer: a systematic review and meta-analysis. J Cancer Res Clin Oncol. 2014;140(9):1537–1549. doi:10.1007/s00432-014-1714-3
   PubMed Web of Science ®Google Scholar
• Warwick R, Mediratta N, Shackcloth M, Shaw M, McShane J, Poullis M. Preoperative red cell distribution width in patients undergoing pulmonary resections for non-small-cell lung cancer. Eur J Cardio-Thor Surg. 2014;45(1):108–113. doi:10.1093/ejcts/ezt275
   PubMed Web of Science ®Google Scholar
• Koma Y, Onishi A, Matsuoka H, et al. Increased red blood cell distribution width associates with cancer stage and prognosis in patients with lung cancer. PLoS One. 2013;8:11. doi:10.1371/journal.pone.0080240
   Web of Science ®Google Scholar
• de Gonzalo-calvo D, de Luxán-delgado B, Rodríguez-González S, et al. Interleukin 6, soluble tumor necrosis factor receptor I and red blood cell distribution width as biological markers of functional dependence in an elderly population: a translational approach. Cytokine. 2012;58(2):193–198. doi:10.1016/j.cyto.2012.01.005
   PubMed Web of Science ®Google Scholar
• Guo Y, Xu F, Lu T, Duan Z, Zhang Z. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev. 2012;38(7):904–910. doi:10.1016/j.ctrv.2012.04.007
   PubMed Web of Science ®Google Scholar
• van Horssen R, Ten Hagen TL, Eggermont AM. TNF-α in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist. 2006;11(4):397–408. doi:10.1634/theoncologist.11-4-397
   PubMed Web of Science ®Google Scholar
• Forhecz Z, Gombos T, Borgulya G, Pozsonyi Z, Prohaszka Z, Janoskuti L. Red cell distribution width in heart failure: prediction of clinical events and relationship with markers of ineffective erythropoiesis, inflammation, renal function, and nutritional state. Am Heart J. 2009;158(4):659–666. doi:10.1016/j.ahj.2009.07.024
   PubMed Web of Science ®Google Scholar
• Gupta D, Lis CG. Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutri J. 2010;9(1):69. doi:10.1186/1475-2891-9-69
   PubMedGoogle Scholar
• Shota S, Saito H, Kono Y, et al. Prognostic significance of pre- and post-operative red-cell distribution width in patients with gastric cancer. J Gastrointestinal Surg. 2019;24(5):1010–1017. doi:10.1007/s11605-019-04392-w
   PubMed Web of Science ®Google Scholar
• Chen B, Dai D, Tang H, et al. Pretreatment hematocrit is superior to hemoglobin as a prognostic factor for triple negative breast cancer. PLoS One. 2016;11(11):e0165133. doi:10.1371/journal.pone.0165133
   PubMed Web of Science ®Google Scholar